Cargando…
Risk prediction score for clinical outcome in atrial fibrillation and stable coronary artery disease
OBJECTIVE: Antithrombotic therapy is essential for patients with atrial fibrillation (AF) and stable coronary artery disease (CAD) because of the high risk of thrombosis, whereas a combination of antiplatelets and anticoagulants is associated with a high risk of bleeding. We sought to develop and va...
Autores principales: | Ishii, Masanobu, Kaikita, Koichi, Yasuda, Satoshi, Akao, Masaharu, Ako, Junya, Matoba, Tetsuya, Nakamura, Masato, Miyauchi, Katsumi, Hagiwara, Nobuhisa, Kimura, Kazuo, Hirayama, Atsushi, Nishihara, Eiichiro, Nakamura, Shinichiro, Matsui, Kunihiko, Ogawa, Hisao, Tsujita, Kenichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10186465/ https://www.ncbi.nlm.nih.gov/pubmed/37173099 http://dx.doi.org/10.1136/openhrt-2023-002292 |
Ejemplares similares
-
Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories
por: Ishii, Masanobu, et al.
Publicado: (2022) -
The impact of kidney function in patients on antithrombotic therapy: a post hoc subgroup analysis focusing on recurrent bleeding events from the AFIRE trial
por: Matsui, Kunihiko, et al.
Publicado: (2022) -
Rivaroxaban Monotherapy in Patients With Atrial Fibrillation and Coronary Stenting at Multiple Vessels or the Left Main Trunk: The AFIRE Trial Subanalysis
por: Ishii, Mitsuru, et al.
Publicado: (2022) -
Antithrombotic Therapy for Atrial Fibrillation and Coronary Artery Disease in Patients With Prior Atherothrombotic Disease: A Post Hoc Analysis of the AFIRE Trial
por: Matsuzawa, Yasushi, et al.
Publicado: (2021) -
Rivaroxaban Underdose for Atrial Fibrillation with Stable Coronary Disease: The AFIRE Trial Findings
por: Arashi, Hiroyuki, et al.
Publicado: (2022)